Hopstem Biotechnology LLC

Established in 2017 and based in Hangzhou, Hopstem Biotechnology LLC operates as a nerve and stem cells developer that focuses on the diagnosis and research of nervous system disease. In December 2020, Hopstem Biotech raised series A+ funding led by new investor Longmen Capital. New investor Guangzhou Huacheng Venture Investment Management also participated in this round. The company focuses on stem cell therapy for neurological diseases.

At the same time, the company provides a variety of innovative scientific research products and services, including high-maturity human nerve cells and internationally leading brain organ products, as well as iPSC reprogramming, clinical-grade iPSC directed differentiation cell product joint development and authorization, and human in vitro disease models , Drug screening, neurotoxicity testing, etc. In the future, the company will promote forebrain nerve precursor cell therapy products, complete the Sino-US IND application for the treatment of ischemic stroke hemiplegia sequelae, promote the construction of cell product production workshops and QC inspection rooms that meet FDA GMP requirements, and accelerate other innovative products and Research and development of pipelines.